biomea fusion
Jacqueline Day is a seasoned professional in clinical trial management with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as a Senior Clinical Trial Associate at Biomea Fusion since February 2022, Jacqueline has led various studies in hematology/oncology and diabetes, focusing on start-up activities and managing patient eligibility processes. Previously, Jacqueline held the position of Senior Clinical Trial Associate at Aimmune Therapeutics, overseeing North American operations for a long-term safety study and managing CRO transitions. Jacqueline's experience also includes roles at Jazz Pharmaceuticals, IQVIA, and Data Services, where responsibilities ranged from managing trial master files to regulatory compliance and financial record-keeping. Early in the career, Jacqueline gained foundational experience in various roles, including data entry and human resources. Jacqueline's educational background includes studies at Hobart and William Smith Colleges from 2010 to 2012.
biomea fusion
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was formed in 2017 by a small group of biotech executives that came together with the common goal of achieving better therapies for patients.